Introduced

Passed Senate

Passed House

Became law

Adjourned sine die. The bill was pending when the session ended, so it did not pass.

Last action · February 20, 2025

To Health Services (S)

Introduced February 18, 2025

Senate

Adjourned Sine Die

2025 Regular Session

SB240

AN ACT relating to Ibogaine research in the Commonwealth.

Create new sections of KRS 218A to define terms; establish the intent of the General Assembly that ibogaine is worthy of clinical research, trials, and studies as a potential viable therapeutic treatment of opioid dependence and any other co-occurring mental health disorders; establish a trust and agency account entitled the ibogaine research fund; establish a process for private entities to apply to the Department of Agriculture for access to funds in the Ibogaine Research Fund.

Opioids Drugs and Medicines Economic Development Public Health Research and Methods State Agencies Agriculture

Read the full text Kentucky Legislature LegiScan

AI-generated. Always verify with primary sources

Plain-language summary

Beta

This bill would officially recognize ibogaine, a naturally derived substance, as worthy of clinical research in Kentucky as a possible treatment for opioid addiction and related mental health conditions. It would create a dedicated fund and set up a process for private organizations to apply to the Department of Agriculture for money to support that research. The bill does not legalize ibogaine for general use but focuses specifically on funding and enabling formal studies. Who it may affect: Kentuckians struggling with opioid dependence, medical and research institutions, and private entities interested in conducting clinical studies.

Open official bill text (PDF)·Report a problem with the summary